FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation

PMA: P240013 · Supplement: S012 · Decision Jul 22, 2025
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation
Trade Name
Sphere-9 Catheter and Affera Ablation System (HexaFlow™ Irrigation Pump; HexaGen™ RF Generator; HexaPulse™ PF Generator)
PMA Number
P240013
Supplement Number
S012
Device Class
FDA Class 3
Product Code
QZI
Generic Name
Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
30-Day Notice Accepted
Decision Code
OK30
Decision Date
July 22, 2025
Date Received
June 23, 2025
Supplement Type
30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

the automation of certain electrical safety tests and an update to an associated manufacturing process for the HexaFlow Irrigation Pump, HexaGen RF Generator, and HexaPulse PF Generator

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QZI Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation